Login
$VTVT
$17.69 -$2.00 (10.16%) Live

$VTVT SEC Filings

Filed On Filing
12 Nov 2026 144
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027

08 Oct 2026 SCHEDULE 13G/A
06 Oct 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

THIRD AMENDED AND RESTATED BY-LAWS of VTV THERAPEUTICS INC. (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 STOCKHOLDERS 3 ARTICLE 3 DIRECTORS 9 ARTICLE 4 COMMITTEES OF THE BOARD 15 ARTICLE 5 OFFICERS 15...

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

29 Jul 2026 SCHEDULE 13G/A
29 Jun 2026 Form 4: Baker Bros. Advisors Lp, Director and 5 others

Granted 12,000 Non-Qualified Stock Option (right to buy)

29 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 26, 2026, vTv Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

29 Jun 2026 Form 4: Spiegelman Daniel K, Director

Granted 6,000 Director stock option (right to buy) ($210K)

29 Jun 2026 Form 4: Akkaraju Srinivas, Director

Granted 6,000 Director stock option (right to buy) ($210K)

29 Jun 2026 Form 4: Al-Marzooqi Fahed, Director

Granted 6,000 Director stock option (right to buy) ($210K)

29 Jun 2026 Form 4: Phillips Anne M., Director

Granted 6,000 Director stock option (right to buy) ($210K)

10 Jun 2026 DEFA14A
13 May 2026 424B2
13 May 2026 8-K: Other Events

We have acted as special counsel to vTv Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the sale from time to time of shares of the Company’s Class A common stock, par value $0.01 per share, having an aggreg...

13 May 2026 S-8
13 May 2026 10-Q
13 May 2026 8-K: Results of Operations and Financial Condition

Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support